REpetitive Assessement of SCOREs in Patients on Dual Antiplatelet Therapy
Launched by UNIVERSITY OF ROMA LA SAPIENZA · May 15, 2018
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
The RE-SCORE registry is a multicenter study aimed at comparing the predictive value of the PRECISE-DAPT score assessed at time of discharge vs. the Delta PRECISE-DAPT score, as assessed every 3 months in PCI patients receiving DAPT.
The primary end-point of the study is the occurrence of bleeding, as defined according to the criteria of the Bleeding Academic Research Consortium (BARC), either in the whole study population or in men vs women.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: All patients undergoing percutaneous coronary intervention and treated with dual antiplatelet therapy for at least 3 months
- • Exclusion Criteria: Contraindications to dual antiplatelet therapy lasting more than 3 months
About University Of Roma La Sapienza
The University of Roma La Sapienza, one of Italy's premier research institutions, is dedicated to advancing medical science and improving patient outcomes through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university harnesses its extensive expertise in diverse fields, including medicine, biotechnology, and public health, to conduct rigorous and ethically sound research. Committed to fostering educational excellence and promoting groundbreaking discoveries, La Sapienza actively engages in clinical trials that aim to address critical health challenges and contribute to the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rome, Please Select, Italy
Patients applied
Trial Officials
Francesco Pelliccia
Study Chair
University of Roma La Sapienza
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials